A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score ...

Currently, no population-based prostate cancer screening program has been established. In the prospective BARCODE1 trial (NCT03857477), 6393 men aged 55 to 69 years from 69 sites in the UK ...

UK’s National Screening Committee will assess whether a screening programme should be rolled out across the country ...

A new study provides the strongest evidence to date on the clinical utility of a polygenic score for prostate cancer ...

According to Research by SNS Insider, Global Prostate Cancer Diagnostics Market Growth is Fueled by Growing Demand for Advanced Biomarker Testing, AI Diagnostics, and Outpatient Screening Services ...

It is to safeguard men like Graham that the Mail has launched a major campaign calling for a nationwide prostate cancer screening programme, similar to that for breast cancer – where all women ...

This is the trouble with prostate cancer screening and is why, despite pressure from charities, the National Screening Committee (NSC) and scientists are reluctant to add it to the list of routine ...

Continuing PSA screening in older men is common practice but not recommended, highlighting the need for clearer guidance.

The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have ...

Overdiagnosis estimates with the polygenic risk score were similar to those reported in prior PSA screening studies. For men at the highest risk of prostate cancer as determined by a polygenic ...